Pyxis Oncology, Inc. (NASDAQ:PYXS) Receives $8.50 Average PT from Brokerages

Shares of Pyxis Oncology, Inc. (NASDAQ:PYXS – Get Free Report) have received an average recommendation of “Buy” from the six brokerages that are currently covering the company, Marketbeat reports. Six equities research analysts have rated the stock with a buy rating. The average twelve-month price objective among brokerages that have covered the stock in the […]

Leave a Reply

Your email address will not be published.

Previous post Inari Medical, Inc. (NASDAQ:NARI) Receives $65.71 Consensus Price Target from Analysts
Next post WisdomTree Emerging Markets High Dividend Fund (NYSEARCA:DEM) Sets New 1-Year High at $43.15